Compare CIM & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIM | NKTR |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.3B |
| IPO Year | 2007 | 1996 |
| Metric | CIM | NKTR |
|---|---|---|
| Price | $8.33 | $37.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $14.17 | ★ $133.08 |
| AVG Volume (30 Days) | ★ 1.4M | 873.9K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 21.33% | N/A |
| EPS Growth | ★ 56.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $27.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $8.11 | $33.40 |
| 52 Week High | $14.18 | $109.00 |
| Indicator | CIM | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 35.38 |
| Support Level | $8.11 | $35.61 |
| Resistance Level | $13.82 | $39.89 |
| Average True Range (ATR) | 0.25 | 1.65 |
| MACD | 0.10 | 1.11 |
| Stochastic Oscillator | 37.14 | 47.89 |
Chimera Investment Corporation is an internally managed REIT whose principal business objective is to provide attractive risk-adjusted returns and distributable income through investment performance linked to mortgage credit fundamentals. Through its mortgage lending, investment management, and advisory services platforms, the Company operates as a fully integrated mortgage business that originates, manages, and invests in a diversified range of mortgage assets. The Company invests, directly or indirectly, generally on a levered basis across a spectrum of mortgage assets, including residential mortgage loans, Non-Agency RMBS, Agency RMBS, Agency CMBS, MSRs, business purpose and investor loans, including RTLs, and other real estate-related assets.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.